Atlas Trials

A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression

Clinical trial NCT02512237 · TERMINATED

Trial details

NCT number
NCT02512237
Sponsor
Zhejiang Medicine Co., Ltd.
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Breast NeoplasmsStomach Neoplasms
Start date
2016-03-01
Primary completion
2017-01-01
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.